WIXOM, Mich., April 15, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, reported today that it has added Alvin L. Crumbliss, Ph.D to its Scientific Advisory Board (SAB). Rockwell's SAB currently advises the Company on clinical development for its investigational, continuous iron-maintenance drug SFP, currently in Phase III clinical studies, as well as other potential indications.
